Cargando…

PTP1B Inhibition Improves Mitochondrial Dynamics to Alleviate Calcific Aortic Valve Disease Via Regulating OPA1 Homeostasis

There are currently no pharmacological therapies for calcific aortic valve disease (CAVD). Here, we evaluated the role of protein tyrosine phosphatase 1B (PTP1B) inhibition in CAVD. Up-regulation of PTP1B was critically involved in calcified human aortic valve, and PTP1B inhibition had beneficial ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Feng, Chen, Jinyong, Hu, Wangxing, Gao, Chenyang, Zeng, Zhiru, Cheng, Si, Yu, Kaixiang, Qian, Yi, Xu, Dilin, Zhu, Gangjie, Zhao, Jing, Liu, Xianbao, Wang, Jian'an
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357565/
https://www.ncbi.nlm.nih.gov/pubmed/35958694
http://dx.doi.org/10.1016/j.jacbts.2022.03.002
Descripción
Sumario:There are currently no pharmacological therapies for calcific aortic valve disease (CAVD). Here, we evaluated the role of protein tyrosine phosphatase 1B (PTP1B) inhibition in CAVD. Up-regulation of PTP1B was critically involved in calcified human aortic valve, and PTP1B inhibition had beneficial effects in preventing fibrocalcific response in valvular interstitial cells and LDLR(−/−) mice. In addition, we reported a novel function of PTP1B in regulating mitochondrial homeostasis by interacting with the OPA1 isoform transition in valvular interstitial cell osteogenesis. Thus, these findings have identified PTP1B as a potential target for preventing aortic valve calcification in patients with CAVD.